What are the primary objectives of Phase I clinical trials?

Prepare for the Drug Discovery and Healthcare Systems Test. Access flashcards and multiple-choice questions with hints and explanations. Ace your exam with our comprehensive resources!

Multiple Choice

What are the primary objectives of Phase I clinical trials?

Phase I trials are about learning how a drug behaves in humans and whether it can be given safely. The main objective is to assess safety, tolerability, and pharmacokinetics (how the body absorbs, distributes, metabolizes, and eliminates the drug). This usually involves starting with a small dose in healthy volunteers or patients and carefully escalating it to identify what doses are safe and how the drug’s levels in the blood change over time. Often researchers look for the maximum tolerated dose and establish a recommended dose range for Phase II. Pharmacodynamics may also be explored to see early biological effects at different doses, but proving effectiveness in large numbers isn’t the goal at this stage. That’s why long-term safety in the general population, definitive efficacy in large populations, and market considerations are addressed in later phases or separate processes. In some cases, especially with higher-risk drugs, Phase I participants are patients rather than healthy volunteers to directly assess safety in the target condition.

Phase I trials are about learning how a drug behaves in humans and whether it can be given safely. The main objective is to assess safety, tolerability, and pharmacokinetics (how the body absorbs, distributes, metabolizes, and eliminates the drug). This usually involves starting with a small dose in healthy volunteers or patients and carefully escalating it to identify what doses are safe and how the drug’s levels in the blood change over time. Often researchers look for the maximum tolerated dose and establish a recommended dose range for Phase II.

Pharmacodynamics may also be explored to see early biological effects at different doses, but proving effectiveness in large numbers isn’t the goal at this stage. That’s why long-term safety in the general population, definitive efficacy in large populations, and market considerations are addressed in later phases or separate processes. In some cases, especially with higher-risk drugs, Phase I participants are patients rather than healthy volunteers to directly assess safety in the target condition.

More practice questions